Wednesday, December 29, 2021 6:22:08 PM
Disastrous Where are the gorillas lol lol lol
Recent BFRI News
- Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 • GlobeNewswire Inc. • 05/21/2026 01:15:00 PM
- Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/14/2026 11:30:00 AM
- Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis • GlobeNewswire Inc. • 05/13/2026 01:00:00 PM
- Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026 • GlobeNewswire Inc. • 05/08/2026 08:00:00 PM
- Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 03/19/2026 01:25:00 PM
- Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 • GlobeNewswire Inc. • 03/09/2026 09:25:00 PM
- Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris • GlobeNewswire Inc. • 03/09/2026 01:15:00 PM
- U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable • GlobeNewswire Inc. • 02/26/2026 02:15:00 PM
- Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities • GlobeNewswire Inc. • 02/17/2026 02:15:00 PM
- Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma • GlobeNewswire Inc. • 02/11/2026 02:15:00 PM
- Biofrontera Reports Positive Phase 3 Data for Ameluz in Actinic Keratosis • IH Market News • 02/09/2026 02:39:24 PM
- Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint • GlobeNewswire Inc. • 02/09/2026 02:15:00 PM
- Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth • GlobeNewswire Inc. • 01/13/2026 01:30:00 PM
- Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones • GlobeNewswire Inc. • 01/08/2026 01:45:00 PM
- Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio • GlobeNewswire Inc. • 12/18/2025 01:45:00 PM
- Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities • GlobeNewswire Inc. • 12/04/2025 02:00:00 PM
- Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT • GlobeNewswire Inc. • 12/02/2025 01:45:00 PM
- Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 11/13/2025 01:15:00 PM
- Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M • GlobeNewswire Inc. • 11/07/2025 01:00:00 PM
- Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025 • GlobeNewswire Inc. • 11/06/2025 09:01:00 PM
- Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG • GlobeNewswire Inc. • 10/23/2025 12:45:00 PM
- Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 • GlobeNewswire Inc. • 09/26/2025 01:15:00 PM
- Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program • GlobeNewswire Inc. • 09/23/2025 01:20:00 PM
- Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk • GlobeNewswire Inc. • 09/16/2025 02:30:00 PM
- Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris • GlobeNewswire Inc. • 08/25/2025 12:25:00 PM
